A civil society view of rare disease public policy in six Latin American countries

Abstract

Patients with rare diseases across the world struggle to access timely diagnosis and state-of-the-art treatment and management of their conditions. Several recently published reviews highlight the importance of country efforts to address rare diseases and orphan drugs policy comprehensively. However, many of these reviews lack depth and detail at the local level, which we believe is necessary for rare disease advocates to identify and prioritize opportunities for strengthening each country's policy framework. We asked leading patient advocates from civil society organizations their views on rare disease public policy in Argentina, Brazil, Chile, Colombia, Mexico, and Peru with a focus on whether specific laws and regulations in these six Latin American countries have been promulgated. From December 2018 to March 2019 we supplemented their perspectives with evidence from accessible literature using key search terms. For each country, we prepared a detailed analysis on how laws or other policy initiatives took shape and the steps taken since to implement them. This allowed us to identify five broad policy categories for subsequent analysis: national laws, national regulations, health system incorporation of rare disease treatments, care delivery, and patient engagement. By describing the different approaches, challenges and timelines across six countries, our research demonstrates that strengthening rare disease policy first requires a common understanding and local consensus of each country's recent past and current situation. Subsequent analysis based on a set of common policy dimensions led us to where we believe salient opportunities lie for each of these countries to strengthen their overall policy framework for rare disease patients.

Multimorbidity patterns among COVID-19 deaths: proposal for the construction of etiological models

“…The wide variety of multimorbidity patterns includes the most frequent co-occurrences that were evident since the beginning of the pandemic, and the co-occurrences with less frequency that appear every time there are more cases, and perhaps it will include orphan diseases, 9 , 10 and those of endemic foci. 11 In these circumstances, low prevalence signifies more clinical complexity.…”

Ethical Issues in Care and Treatment of Neuronal Ceroid Lipofuscinoses (NCL)–A Personal View

“…NCL belong to the thousands of diseases for which the fact of their rarity adds to suffering of patients and hampers the development of treatments. Rarity leads to insufficient knowledge of the course of disease and of disease mechanisms and to too few participants in clinical trials of proposed new therapies (29,30). Rarity creates a host of questions for stakeholders in the field: affected patients with their families, patient organizations and supporting foundations, healthcare providers (medical services and pharmaceutical industry), insurance or other payments systems, public health policymakers, and research institutions.…”

Clinical trials for genetic diseases in Latin America

“…Plans/Laws focused on diagnosis and care of people living with rare diseases, starting in 2009 in Brazil with the National Policy for Integral Care in Clinical Genetics, broadened and implemented in clinical practice by the Policy for People Living with Rare Diseases in 2014, and followed by similar policies issued in Colombia, Argentina, Peru, Mexico, and Chile (Mayrides, Ruiz de Castilla, & Szelepski, 2020).…”